HOME >> BIOLOGY >> NEWS
FDA clears Berlex Laboratories Mirena (R), new form of long-acting contraception meets need for U.S. women

Montville, NJ, December 6, 2000 Berlex Laboratories, Inc., the U.S. subsidiary of Schering AG, Germany (NYSE: SHR), announced today that the U.S. Food and Drug Administration (FDA) approved MIRENA(R) (levonorgestrel-releasing intrauterine system), a convenient, innovative contraceptive that is as effective in preventing pregnancy as tubal ligation (better than 99 percent) and lasts for five years, or until removed.

Available for 10 years in Europe, MIRENA has been used by approximately two million women worldwide and will be available for the first time in the U.S. in the first quarter of 2001. "Women in European and Asian countries have used MIRENA successfully and safely." says Felicia Stewart, MD, Incoming Chair of the Association of Reproductive Health Professionals. "For many women in the U.S. there has been a limited choice in convenient, reliable and reversible long-acting contraception. MIRENAs availability gives these women a choice they need and deserve."

In addition to preventing pregnancy, MIRENA use may result in a change in bleeding patterns. In the first three to six months following insertion, there may be an increase in intermenstrual bleeding. After this, a womans period may become shorter and lighter. Some women experience an absence of menstrual bleeding after one year.

MIRENA does not contain estrogen. It delivers a low dose of the progestin levonorgestrel directly to the lining of the uterus. Studies suggest several mechanisms that prevent pregnancy: thickening of cervical mucus, which prevents the passage of sperm, inhibition of sperm mobility and inhibition of endometrial growth. Berlex will market MIRENA under a license from The Population Council, which initially developed the contraceptive.

"MIRENA is the first in a series of major new products that Berlex will bring to market, and its introduction marks the beginning of an expansion in the Berlex position in women's health," said Reinhard Franzen, Vice
'"/>

Contact: Julie Mandell
julie_mandell@berlex.com
973-487-2592
Porter Novelli
6-Dec-2000


Page: 1 2 3

Related biology news :

1. Wildland fires: After the smoke clears
2. FDA clears for market new diagnostic test for lupus
3. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin
4. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
5. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
6. Study finds two-thirds of unplanned pregnancies in women using contraception
7. Proteins that bind to sperm offer clues to male fertility and possible male contraception
8. Chemistry meets Biology
9. The American Society for Biochemistry and Molecular Biology meets in Boston
10. Experimental Biology 2004 meets in Washington, D.C. April 17-21
11. Experimental Biology 2003 meets in San Diego April 11-15

Post Your Comments:
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
Cached News: